Clinical trials: Suppurative Hidradenitis
Hidradenitis Suppurativa
Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa
The trial enrolls patients with moderate to severe Hidradenitis Suppurativa (HS). The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 weeks in these patients.
- Trial name
- NCT03001622
- Testing
- IFX-1
- Where
- Greece
- Volunteers
- 12 people
- Sponsor
- InflaRx GmbH
Hidradenitis Suppurativa
Hidradenitis Suppurativa Phase 2b Study of Izokibep
Izokibep is a potent and selective inhibitor of interleukin 17A (IL-17A) that is being developed for treatment of hidradenitis suppurativa (HS).
- Trial name
- NCT05355805
- Testing
- Izokibep
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 205 people
- Sponsor
- ACELYRIN Inc.
Hidradenitis Suppurativa, Scarring
Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppurativa Patients
Single center, open-label, baseline-controlled study evaluating the use of a Sciton fractionated ablative laser in the treatment of Hidradenitis Suppurativa (HS) scarring.
- Trial name
- NCT05470322
- Testing
- Er: YAG laser
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Hidradenitis Suppurativa (Acne Inversa)
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to…
- Trial name
- NCT02421172
- Testing
- CJM112
- Where
- 16 sites in United States, Denmark and 3 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on…
- Trial name
- ANIMA - Italy (NCT07543419)
- Where
- 16 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa, Quality of Life
Impact of Hidradenitis Suppurativa on Quality of Life Functions
The goal of this study is to get a better understanding of the impact of Hidradenitis Suppurativa (HS) on the quality of life of patients with this condition.
- Trial name
- NCT03288337
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Montefiore Medical Center
HYDRADENITIS
15% TOPICAL RESORCINOL FOR HURLEY I-II HIDRADENITIS SUPPURATIVA.
Prospective, observational cross-sectional study to evaluate the response of patients with HS I-II to monotherapy treatment of topical resorcin 15%, taking into account its safety, impact on quality of life and subclinical…
- Trial name
- NCT04099212
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Hidradenitis Suppurativa
Pathophysiological Basis of Hidradenitis Suppurativa
HS is a chronic inflammatory disease manifested by recurrent inflammatory nodules, abscesses and tunnels under the skin. This disease is characterized by an inflammatory process that takes place in hair follicles, sebaceous…
- Trial name
- NCT06370052
- Testing
- excision
- Volunteers
- 50 people
- Sponsor
- Clinical Hospital Center Rijeka
Hidradenitis Suppurativa, Acne Inversa
Anifrolumab for Hidradenitis Suppurativa
This clinical trial aims to study if a drug called anifrolumab works to treat Hidradenitis Suppurativa (HS) as well as its effect in quality of life before and after treatment.
- Conditions
- Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
- Trial name
- NCT06374212
- Testing
- Anifrolumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Urticaria, Idiopathic, Hidradenitis
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days.
- Conditions
- Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
- Trial name
- NCT06555328
- Testing
- CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment
- Where
- 29 sites in United States, Bulgaria and 4 more
- Volunteers
- 73 people
- Sponsor
- InflaRx GmbH
Hidradenitis Suppurativa (HS)
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.
- Trial name
- SHARPS (NCT02808975)
- Testing
- Adalimumab
- Where
- 55 sites in United States, Belgium and 21 more
- Volunteers
- 206 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa
The purpose of this research study is to further evaluate the efficacy of two treatment regimens for the treatment of hidradenitis suppurativa. This is a randomized controlled study.
- Trial name
- NCT01063270
- Testing
- Clindamycin & Rifampin, Clindamycin + Rifampin along with NdYag Laser treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Henry Ford Health System
Hidradenitis Suppurativa
Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser
Patients with bilateral hidradenitis in the axilla, groin and/or inframammary will be treated on one side with the Alexandrite hair removal laser. The other side will serve as the control.
- Trial name
- NCT03054155
- Testing
- Alexandrite Laser
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Hidradenitis Suppurativa
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together.
- Trial name
- NCT07244263
- Testing
- Zasocitinib (Dose A)
- Where
- 49 sites in United States, Australia and 6 more
- Volunteers
- 90 people
- Sponsor
- Takeda
Axillary Hidradenitis Suppurativa
Perforator Flaps for Axillary Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a recurrent inflammatory disease (< 2 episode /6 months) with 1%-4% prevalence in Europe. Suppurating lesions are painful and involve one or more regions (axilla, genitofemoral, perineum, gluteal…
- Trial name
- HS-PAX (NCT03784313)
- Testing
- skin repair by axillary perforator flaps, skin repair by secondary wound healing
- Where
- France
- Volunteers
- 88 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hidradenitis Suppurativa
Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa
The current surgical management for severe Hidradenitis suppurativa (HS) involves wide excision of affected skin, resulting in a large soft tissue defect.
- Trial name
- HIDRA (NCT04325607)
- Testing
- Excision of HS followed by NPWTi, Excision of HS followed by NPWT
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Hidradenitis Suppurativa (HS)
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
- Trial name
- STOP-LTR (NCT06855498)
- Testing
- povorcitinib
- Where
- 306 sites in United States, Argentina and 18 more
- Volunteers
- 600 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
- Trial name
- COMPASS 2-HS (NCT07287644)
- Testing
- BFB759
- Where
- 64 sites in United States, Bulgaria and 5 more
- Volunteers
- 210 people
- Sponsor
- Bluefin Biomedicine, Inc.
Hidradenitis Suppurativa
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
- Trial name
- Regulate-HS (NCT06361836)
- Testing
- SBT777101
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sonoma Biotherapeutics, Inc.
Hidradenitis Suppurativa
Defects of Keratinocytes Function in Dermatologic Patients
NOTCH signaling in the skin exerts a pivotal role in the regulation of normal keratinocytes turnover by mediating the balance between proliferation, differentiation, apoptosis and autophagic flux progression.
- Trial name
- NCT06324552
- Where
- 15 sites in Austria, Belgium and 4 more
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- IRCCS Burlo Garofolo